This modification results in dramatically different properties
The resulting product is 2-methoxyestradiol
Studies have shown that GLP-1 agonists can trigger effects in the brain, the heart, the liver, the pancreas, the stomach, and the musclesmeaning that they could have implications for conditions other than type 2 diabetes and obesity, such as heart disease, kidney disease, liver disease, and even neurological conditions such as Alzheimer's disease
Labeling vials immediately after reconstitution prevents this scenario entirely
Prior Presentation This study has been presented as a poster at the 80th Scientific Sessions of the American Diabetes Association, June 1216, 2020
scrape or copy content for a competing service